Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and ...

Pfizer (PFE) stock is in focus as the company starts Phase 3 infant trials for the 25-valent pneumococcal vaccine after ...

May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...

Pfizer's 25vPnC pneumococcal vaccine shows up to 15-fold higher antibody levels in infants, advancing to late-stage trials ...

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...